Comparative Pharmacology
Head-to-head clinical analysis: TRIAVIL 4 25 versus TRIAVIL 4 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIAVIL 4 25 versus TRIAVIL 4 50.
TRIAVIL 4-25 vs TRIAVIL 4-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TRIAVIL (amitriptyline/perphenazine) combines a tricyclic antidepressant (amitriptyline) that inhibits reuptake of norepinephrine and serotonin, and a phenothiazine antipsychotic (perphenazine) that blocks dopamine D2 receptors, serotonin 5-HT2 receptors, and alpha-adrenergic receptors, with additional anticholinergic, antihistaminergic, and antiemetic properties.
Amitriptyline is a tricyclic antidepressant that inhibits reuptake of serotonin and norepinephrine. Perphenazine is a typical antipsychotic that blocks dopamine D2 receptors.
One tablet (perphenazine 4 mg / amitriptyline 25 mg) orally 3 to 4 times daily. Maximum: 8 tablets daily.
One tablet (4 mg perphenazine / 50 mg amitriptyline) orally three times daily to four times daily. Maximum: 8 tablets per day.
None Documented
None Documented
Amitriptyline: 13–36 hours (mean ~21 hours); perphenazine: 8–21 hours (mean ~12 hours); steady-state achieved in 3–10 days.
Amitriptyline: 15-40 hours (mean 20-30 hours); perphenazine: 9-12 hours; clinical context: steady-state achieved within 5-7 days, dosing adjustments needed in hepatic impairment.
Renal: ~70% as metabolites (including amitriptyline and perphenazine metabolites) and <5% unchanged; fecal: ~30% via bile; enterohepatic recirculation occurs.
Renal: 50-60% as metabolites (amitriptyline and perphenazine), <5% unchanged; fecal: 20-30% (primarily perphenazine metabolites); biliary: minor route for perphenazine.
Category C
Category C
Antidepressant-Antipsychotic Combination
Antidepressant-Antipsychotic Combination